结节性硬化症相关血管平滑肌脂肪瘤患者的疾病监测与治疗模式
本研究利用结节性硬化症自然史数据库,描述2006-2013年16家参与诊所入组的1300余例结节性硬化症患者中相关血管平滑肌脂肪瘤的监测与治疗模式。621例结节性硬化症相关血管平滑肌脂肪瘤患者中,84%在诊断后至少接受1次监测检查,最常用为磁共振成像(65%)、超声(62%)和计算机断层扫描(41%);2000至2012年间磁共振成像占比逐渐增加。25%的患者接受治疗,最常见为栓塞(10%)、依维莫司(9%)、西罗莫司(6%)和肾切除术(6%);肾切除术率随时间下降,2011年和2012年无肾切除术;以mTOR抑制剂一线治疗的71例患者中未报告后续手术。
要点
- 621例结节性硬化症相关血管平滑肌脂肪瘤患者中,84%在诊断后至少接受1次监测检查。
- 最常用监测检查为磁共振成像(65%)、超声(62%)和计算机断层扫描(41%)。
- 25%的患者接受治疗,最常见为栓塞(10%)、依维莫司(9%)、西罗莫司(6%)和肾切除术(6%)。
核心结论
- 2000至2012年间,结节性硬化症相关血管平滑肌脂肪瘤患者的磁共振成像使用增加。
- 多数结节性硬化症相关血管平滑肌脂肪瘤患者未接受治疗。
- 研究期间肾切除术使用减少,在接受mTOR抑制剂的患者中尤为罕见。
研究设计与样本
- 本研究使用结节性硬化症自然史数据库,该数据库包含2006-2013年16家参与诊所入组的1300余例结节性硬化症患者的人口学、受累区域、诊断和治疗信息。
- 评估了患者特征、血管平滑肌脂肪瘤监测检查和血管平滑肌脂肪瘤治疗。
主要发现
- 621例结节性硬化症相关血管平滑肌脂肪瘤患者中,54%为女性,77%为白人。
- 结节性硬化症诊断中位年龄小于1岁,血管平滑肌脂肪瘤诊断中位年龄为9.8岁。
- 84%的患者在血管平滑肌脂肪瘤诊断后至少接受1次监测检查,最常用为磁共振成像(65%)、超声(62%)和计算机断层扫描(41%)。
- 2000至2012年间,磁共振成像在监测检查总数中所占比例逐渐增大。
- 诊断后155例(25%)患者接受血管平滑肌脂肪瘤治疗,从诊断到首次治疗的中位时间为3.8年,最常见治疗为栓塞(10%)、依维莫司(9%)、西罗莫司(6%)和肾切除术(6%);肾切除术率随时间下降,2011年和2012年未进行肾切除术;以mTOR抑制剂一线治疗的71例患者中未报告后续手术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To use the tuberous sclerosis complex (TSC) Natural History Database to describe monitoring and treatment patterns among patients with TSC-related angiomyolipomas (AMLs). METHODS: This study used the TSC Natural History Database, which contains demographics, affected areas, diagnosis, and treatments for more than 1300 patients with TSC enrolled in 16 participating clinics during 2006-2013. Patient characteristics, AML monitoring tests, and AML treatments were assessed. RESULTS: Among the 621 patients with TSC-related AMLs, 54% were female; 77% were Caucasian. Median age at TSC diagnosis was <1 year, whereas median age at AML diagnosis was 9.8 years. Most patients (84%) had at least 1 monitoring test following AML diagnosis. The most commonly used tests were magnetic resonance imaging (MRI; 65% of patients), ultrasound (62%), and computed tomography (41%). Between 2000 and 2012, MRI made up an increasingly large proportion of the total number of monitoring tests. Once diagnosed, 155 (25%) of patients received treatment for AML. The median time from diagnosis to first treatment was 3.8 years. The most common treatments were embolization (10%), everolimus (9%), sirolimus (6%), and nephrectomy (6%). The rate of nephrectomies declined over time, with none conducted during 2011 and 2012. No subsequent surgeries were reported among the 71 patients who received mTOR inhibitor as first-line therapy. CONCLUSION: The use of MRIs increased between 2000 and 2012 among patients with TSC-AML. The majority of these patients did not receive treatment for AML. Use of nephrectomy decreased over the study period and was particularly rare in patients who received an mTOR inhibitor.
引用
- Swallow E, King S, Song J, et al. Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas. Urology. 2017. PMID: 28263820. doi:10.1016/j.urology.2017.02.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。